Cochlear shares jump 6% on guidance upgrade

Demand for Cochlear's products has been stronger than expected in FY 2024.

| More on:

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 3 April 2025

Two colleagues at work looking at a tablet and smiling at a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares are on the move on Thursday morning.

At the time of writing, the hearing solutions company's shares are up 6% to $310.00.

Why are Cochlear shares charging higher?

Investors have been fighting to get hold of the company's shares today after it released an update on its guidance for FY 2024.

According to the release, Cochlear has had a stronger than expected first half for cochlear implant revenue and therefore believes it will now outperform its guidance over the full year.

As a reminder, Cochlear was guiding to underlying net profit of $355 million to $375 million for FY 2024.

However, today's update reveals that it is now guiding to underlying net profit in the range of $385 million to $400 million, which will represent a 26% to 31% increase on FY 2023's result.

First half update

While its results will be released in full later this month on 19 February, management has given investors a taste of what's to come.

It advised that it expects to report a first half sales revenue increase of 25% (20% in constant currency) to $1,113 million with underlying net profit of $192 million.

Cochlear's CEO and President, Dig Howitt, commented:

Cochlear implant trading conditions have been strong across the first half, with units growing 14%. We have maintained the market share gains made in FY23 and market growth has continued to be robust across both developed and emerging markets, as well as all age segments – children, adults and seniors. The key change to our expectations is that we now expect to achieve 10-15% growth in our cochlear implant units for FY24 compared to the high single-digit growth expected in August.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »